Becton Dickinson promises a brighter future for investors though its share price still reflects the dark days of 1999
This article was originally published in Clinica
Becton Dickinson officials urged investors at the company's annual meeting last week not to be discouraged by 1999's disappointing results.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.